The effects of atorvastatin on the kidney injury in mice with pulmonary fibrosis.

Karatug Kacar A. , Yildirim M. , Bolkent Ş. , Oztay F.

The Journal of pharmacy and pharmacology, cilt.71, ss.1301-1310, 2019 (SCI Expanded İndekslerine Giren Dergi) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 71
  • Basım Tarihi: 2019
  • Doi Numarası: 10.1111/jphp.13128
  • Dergi Adı: The Journal of pharmacy and pharmacology
  • Sayfa Sayıları: ss.1301-1310


Objectives The present study investigated the effects of atorvastatin on kidney injury in mice with pulmonary fibrosis (PF). Methods Adult mice were divided into four groups: mice treated with intratracheal bleomycin (I) and their controls (II), and mice treated with atorvastatin for 10 days after 7 days from bleomycin treatment (III) and their controls (IV). Mice were dissected on the 21st day. Key findings Mononuclear cell infiltrations, injured proximal tubule epithelium and p-c-Jun level increased, while cell proliferation and the levels of p-SMAD2, ELK1, p-ELK1, p-ATF2 and c-Jun decreased in the kidney tissue of mice with PF. The atorvastatin treatments to mice with PF resulted in significant increases at the TGF-beta activation, cell proliferation and kidney damage and decreases in the levels of p-SMAD2, p-ELK1, p-ATF2 and p-c-Jun, but not change the p-SMAD3, ELK1 and ATF2 in kidneys. Conclusions The depletion of MAPK signals, rather than SMAD signalling, is effective in kidney damage of mice with PF. Atorvastatin did not regress kidney damage in these mice, whereas it increases the kidney injury. The c-Jun-mediated JNK signals could help kidney repair through cell proliferation. The treatment time and doses of atorvastatin should be optimized for regression of kidney damage.